ABOUT · THE PUBLISHER
About Medicine TB-500
A depth-layered reading of the published TB-500 and thymosin beta-4 literature, reported plainly — what the studies measured, and what they did not.
What this site is
Medicine TB-500 is a depth-layered reading of the peer-reviewed research literature on TB-500 and its parent protein, thymosin beta-4. Nothing is sold, supplied, or dispensed here; no clinician is on staff; and no line on the site is medical advice, a prescription, or a treatment recommendation.
The site is built as a spatial reading: a depth-layered map where each finding sits in its own zone — mechanism, wound healing, the anti-fibrotic record, the safety signals, the regulatory status — and where every quantitative claim resolves to a numbered citation. The design language is a deliberate one, but the content discipline underneath it is ordinary: report what the studies found, attribute it, and mark the gaps.
Why the name says "medicine"
The word "medicine" in this site's name is editorial framing — the lens through which the publisher reads the literature — not a claim about services the site provides. We do not diagnose, treat, prescribe, or consult. There is no clinic behind this digest, no pharmacy, and no prescriber. The honest framing matters here because TB-500 is, in fact, an unapproved research and veterinary-context substance, and a site that read otherwise would be misreading its own subject.
That is also why the editorial spine of this project is the gap, not just the finding. The single most important fact about TB-500 is an identity one — the marketed seven-mer is not the full-length protein that most efficacy studies used — and the most important evidentiary fact is an absence: no completed controlled human trial of the heptapeptide exists. A digest that surfaced the promising animal numbers without those two caveats would be advertising, not editorial. This one keeps both in view on every page.
How we cite
Every number on this site — a dose, a percentage, a half-life, a study's species and route — maps to a source in the references and citations list, with a DOI or PubMed identifier where one exists. Regulatory facts on the legal-status page are drawn from FDA's own pages and stated in the present tense. Where a future FDA action is discussed, it is framed strictly as a scheduled event under review, never as a decision. If a claim is not in the published record, it is not on this site.